The COHCCC Protocol Review and Monitoring System is implemented through the activities of its Cancer Protocol Review and Monitoring Committee (CPRMC). The CPRMC focuses on scientific merit, scientific priorities, and scientific progress of Cancer Center clinical research, working collaboratively with the Data and Safety Monitoring Committee (DSMC) in accordance with the COHCCC Data and Safety Monitoring Plan. The role of the CPRMC is to: 1) maintain and improve the quality of institutional clinical research;2) prioritize clinical research conducted by Cancer Center members;and 3) provide a pathway for innovative clinical cancer research to access Cancer Center shared resources and protocol specific research support. Committee review and voting is required for all new trials, amendments, and annual continuation reviews. The scientific review process for new trials includes an evaluation of study design, scientific rationale, feasibility and biostatistical methodology. Annual continuation reviews include an examination of actual vs. expected accrual and continued relevance of the research question. The CPRMC provides a centralized mechanism for evaluating the scientific merit of all cancer clinical trials and prioritizes studies for access to COHCCC clinical trial resources. Funding is requested for partial salary support for the Chair of the CPRMC, the Director of Scientific and Safety Review, two Protocol Analysts and a Clerical Specialist supporting the work of protocol review and monitoring. All other remaining costs are covered by institutional funds.
It is of critical importance that the COHCCC have a mechanism for assuring adequate internal oversight of the scientific aspects of all cancer clinical trials. The PRMS addresses this. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.
|Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141|
|Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828|
|Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118|
|Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165|
|Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :|
|Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5|
|Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328|
|Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171|
|Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520|
|Oh, Eunjin; Ahn, Miwon; Afelik, Solomon et al. (2018) Syntaxin 4 Expression in Pancreatic ?-Cells Promotes Islet Function and Protects Functional ?-Cell Mass. Diabetes 67:2626-2639|
Showing the most recent 10 out of 1396 publications